Delivery Order SPE2DB20D9135-SPE2DB23FZW32

Award Date 5/15/23
Potential Completion Date 6/6/23
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $37,137.60, is for the delivery of XOLAIR 150 MG/ML syringes to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,160.55, is for the delivery of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, with a period of performance through May 14, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $7,737.00, is for the delivery of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, a specialized pharmaceutical product. The contract is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,326.62, covers the delivery of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, a specialty pharmaceutical product, to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant Indefinite Delivery Contract (IDC) with...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $18,568.80, is for the supply of XOLAIR 150 MG/ML syringes. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price delivery orders for...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of XOLAIR 150 MG/ML syringes. The total ceiling value of the order is $77,370.00, with an ultimate completion date of September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,321.10 contract is for the supply of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, with a period of performance through February 28, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,428.78 contract is for the supply of Xolair 75 mg/0.5 ml syringes. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm fixed-price delivery orders for a wide range of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,642.20, is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized medication. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm fixed-price...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,268.00 delivery order is for the supply of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, which is a specialized pharmaceutical product. The award is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999, which runs through December 31,...
  • SPE2DB20D9135
    Indefinite Delivery Contract
  • SPE2DB20D9135-SPE2DB23FZW32
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, worth up to $3,094.80, covers the delivery of XOLAIR 75 MG/0.5 ML syringes to support the recurring medical supply needs of military health facilities.

DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items. This IDC, which runs through December 31, 2025, solidifies DMS Pharmaceutical Group's position as a critical supplier in the federal pharmaceutical supply chain, providing both routine and specialized medications to Department of Defense (DoD) healthcare facilities worldwide. The contract does not have a set-aside designation.

Generated 1/9/25, 9:11 AM